338 related articles for article (PubMed ID: 30574813)
1. Bioequivalence studies with anti-TNF biosimilars.
Gimeno-Gracia M; Gargallo-Puyuelo CJ; Gomollón F
Expert Opin Biol Ther; 2019 Oct; 19(10):1031-1043. PubMed ID: 30574813
[No Abstract] [Full Text] [Related]
2. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
Zhou X; Chen Z; Bi X
Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
[No Abstract] [Full Text] [Related]
4. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
[TBL] [Abstract][Full Text] [Related]
5. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
Chang S; Hanauer S
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar infliximab: an expert view.
Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
[TBL] [Abstract][Full Text] [Related]
7. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
11. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
12. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
Reinisch W; Louis E; Danese S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
[TBL] [Abstract][Full Text] [Related]
13. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in Dermatology: Current Situation (Part II).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
17. CT-P13 in the treatment of rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
[TBL] [Abstract][Full Text] [Related]
18. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
19. Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab.
Derzi M; Shoieb AM; Ripp SL; Finch GL; Lorello LG; O'Neil SP; Radi Z; Syed J; Thompson MS; Leach MW
Regul Toxicol Pharmacol; 2020 Apr; 112():104587. PubMed ID: 32006671
[TBL] [Abstract][Full Text] [Related]
20. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]